Titlebook: Continuous Dopaminergic Stimulation in Parkinson’s Disease; Proceedings of the W J. A. Obeso,R. Horowski,C. D. Marsden Conference proceedin

正常

Chronic s.c. Lisuride in Parkinson’s disease — motorperformance and avoidance of psychiatric side ef L-deprenyl. L-Dopa infusions are efficient, but not applicable for longer use. S. c.-Lisuride-infusions reduce markedly motor-response fluctuations, dystonias and hyperkinesias, but bear the risk of inducing confusion or even psychosis. In patients with coexisting response fluctuations and psychiat

集聚成團(tuán)

Continuous subcutaneous lisuride infusions in Parkinson’s diseasewith continuous (24 hour) subuctaneous lisuride infusions together with a reduced dose of levodopa (plus DDI). An improvement in motor performance was seen in 10 patients, with a mean increase in percentage of waking time spent “on” of 32 per cent (range 13–59 percent). However, adverse effects were

BAN

A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson’s disease-release form, Madopar HBS, which attenuated fluctuations in patients with end-of-dose impairment, but achieved only moderate improvement in patients with on-off phenomena..In a second phase of the trial, 4 parkinsonians exhibiting the most severe fluctuations of mobility and the poorest response to

CLAP

Aspirin

Lisuride infusion pump in Parkinson’s disease. A report of two cases treated with Lisuride by means of a portable subcutaneous infusion pump are reported..Results obtained show significant improvement in disability through a net increase in the number of hours spent “on”. Dyskinesias remained unmodified. Limiting psychiatric side effects were observed in one of the

背心

紅潤

600

提名的名單

鞭打

Effect of chronic subcutaneous minipump infusion of lisuride upon locomotor activity of ratscomotor activity was measured at 5 hours, 1, 7 and 14 days after implantation. Thereafter the minipumps were removed and 1, 7 and 21 days later the locomotor activity was recorded after a subcutaneous challenge dose of lisuride 0.1 mg/kg. In the course of continuous infusion the lisuride-treated rat